test

Developmental Therapeutics

Nikolai Alexandrovich Podoltsev MD, PhD

Assistant Professor of Medicine (Hematology); Associate Director of the Hematology/Oncology Fellowship Program

Clinical Interests

myeloprolipherative neoplasms (MPN); myelodysplastic syndromes (MDS); acute leukemias


Board Certifications

2010
Hematology (Internal Medicine), Board Certified
2010
Medical Oncology, Board Certified
2000
Internal Medicine, Board Certified

Patient Care Locations

nikolai_podoltsevfaculty-clinicsfalsetruetrue6truefalsefalse

Clinical Trials

ConditionsStudy Title
Myeloid and Monocytic LeukemiaA Randomized Phase III Study of Standard Cytarabine Plus Daunomycin (7+3) Therapy versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Antiphospholipid Syndrome (APS)Comparison of Gut Commensal Bacteria Between Persistently anti-gamma2 Glycoprotein-I Positive Patients and Antiphospholipid Antibody Negative Patients
Myeloid and Monocytic LeukemiaE2905: Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Leukemia, otherA Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (=65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
Lymphoid LeukemiaE1912: A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

More Clinical Trials...

Edit Profile